EGFR and non-small cell lung carcinoma: Last, it is essential to consider whether baseline genomic features and longitudinal detection of MRD could help in implementing more personalized treatment for early-stage and locally advanced EGFR-mutant NSCLC, which warrants a longer duration of surveillance.